This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aafia's Most Recent Article

Chelsea Therapeutics: Northera FDA Panel Live Blog

01/14/14 - 07:49 AM EST

A panel of experts is debating the merits of Chelsea's drug as a treatment for a debilitating form of low blood pressure. Follow along with our live blog.

read more >

Other Articles by Aafia

Free Reports

Unigene Faces Do-or-Die FDA Panel Tuesday Unigene Faces Do-or-Die FDA Panel Tuesday

03/04/13 - 06:00 AM EST

An FDA panel's decision on the safety of calcitonin to treat osteoporosis will have a big impact on Unigene's stock price.

read more >
Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

02/19/13 - 06:00 AM EST

TheStreet contributor Aafia Chaudhry says prior study results raise the risk of a bad outcome in Ziopharm's phase III sarcoma drug trial.

read more >
Sarepta Bear Speaks: Eteplirsen Accelerated Approval Will Be Denied Sarepta Bear Speaks: Eteplirsen Accelerated Approval Will Be Denied

02/11/13 - 07:00 AM EST

Eteplirsen data are biased and flimsy, and FDA will ask for another clinical trial, says TheStreet contributor Aafia Chaudhry.

read more >
Depomed Bear Case: FDA Panel Will Ding Serada Depomed Bear Case: FDA Panel Will Ding Serada

02/04/13 - 08:35 AM EST

New contributor Aafia Chaudhry explains why she believes Depomed's hot flash drug has no future.

read more >
Page 1 of 1
< Previous
Next >
Top Rated Stocks Top Rated Funds Top Rated ETFs